The Clinical Promise of Nano-Based Drug Delivery: Precision, Efficacy, and Safety
Abstract views: 65
/ 
PDF downloads: 58
DOI:
https://doi.org/10.61705/gcy75k24Keywords:
Nano-based drug delivery systems, Nanoparticles, Advanced therapies, Personalized medicine, Clinical translation, NanomedicineAbstract
Nano-based drug delivery systems (NDDS) are novel technologies that use nanoparticles to improve the delivery of therapeutic agents for various diseases. Nanoparticles have distinctive properties, such as small size, large surface area, tuneable functionality, and controlled release, that enable them to overcome the limitations of conventional drug delivery methods. NDDS can be fabricated from different materials, such as lipids, polymers, and inorganic substances, and can be customized for specific applications by altering their size, shape, and surface chemistry. NDDS can employ various mechanisms to transport drugs to their target sites, such as passive targeting, active targeting, and stimuli-responsive systems, that enhance specificity, efficacy, and safety. NDDS have demonstrated significant potential in pre-clinical and clinical studies for treating diseases, especially cancer, infectious diseases, and inflammatory conditions, by increasing drug solubility, stability, and bioavailability, reducing systemic toxicity and drug resistance, and overcoming biological barriers. NDDS also offer the possibility of advanced therapies that integrate multiple functions, such as theragnostic, multi-drug delivery, and combined modalities, as well as personalized nanomedicine that tailors NDDS to individual patients' needs. NDDS face considerable challenges in terms of biocompatibility, toxicity, manufacturing, scale-up, and regulatory approval, but ongoing research and collaboration efforts are addressing these issues and accelerating their clinical translation. NDDS represent a revolutionary field of nanomedicine that holds immense potential for transforming healthcare delivery and improving patient outcomes across a broad range of diseases.
References
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2(12), 751-760.
Blanco, E., Shen, H., & Ferrari, M. (2015). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotechnology, 33(9), 941-951.
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: progress, challenges and opportunities. Nature Reviews Cancer, 17(1), 20-37.
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021). Engineering precision nanoparticles for drug delivery. Nature Reviews Drug Discovery, 20(2), 101-124.
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S & Shin, H. S. (2018). Nano based drug delivery systems: recent developments and future prospects. Journal of Nanobiotechnology, 16(1), 71.
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. (2016). Analysis of nanoparticle delivery to tumors. Nature Reviews Materials, 1(5), 16014.
National Institutes of Health (NIH) - National Cancer Institute (NCI) Alliance for Nanotechnology in Cancer (https://nano.cancer.gov/)
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018). Progress and challenges towards targeted delivery of cancer therapeutics. Nature Communications, 9(1), 1-12.
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016). Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharmaceutical Research, 33(10), 2373-2387.
Ventola, C. L. (2017). Progress in nanomedicine: approved and investigational nanodrugs. Pharmacy and Therapeutics, 42(12), 742.
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2010). Nanotheranostics and image-guided drug delivery: current concepts and future directions. Molecular Pharmaceutics, 7(6), 1899-1912.
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008). Factors affecting the clearance and biodistribution of polymeric nanoparticles. Molecular Pharmaceutics, 5(4), 505-515.
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015). Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. Journal of Controlled Release, 200, 138-157.
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012). Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chemical Society Reviews, 41(7), 2971-3010.
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of Controlled Release, 65(1-2), 271-284.
Barenholz, Y. (2012). Doxil®—the first FDA-approved nano-drug: lessons learned. Journal of Controlled Release, 160(2), 117-134.
Mitragotri, S., Anderson, D. G., Chen, X., Chow, E. K., Ho, D., Kabanov, A. V., ... & Langer, R. (2015). Accelerating the translation of nanomaterials in biomedicine. ACS Nano, 9(7), 6644-6654.
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008). Active targeting schemes for nanoparticle systems in cancer therapeutics. Advanced drug delivery reviews, 60(15), 1615-1626.
Torchilin, V. P. (2014). Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nature reviews Drug discovery, 13(11), 813-827.
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017). Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Advanced Drug Delivery Reviews, 108, 25-38.
Duncan, R., & Gaspar, R. (2011). Nanomedicine (s) under the microscope. Molecular Pharmaceutics, 8(6), 2101-2141
Additional Files
Published
Issue
Section
License
Copyright (c) 2024 International Journal of Medical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
